ZOETIS CENTER FOR TRANSBOUNDARY AND EMERGING DISEASES

SARS-CoV-2 EXPERIMENTAL VACCINE

Zoetis to make available an experimental COVID-19 vaccine for zoos and conservatories

You do everything you can to provide the highest level of comfort, care and health for your animals. As research continues, we are learning that many species of animals, including dogs; domestic cats; mink; ferrets; great apes; small primates; big cats; and small carnivores, such as meerkats and prairie dogs, are all susceptible to the SARS-CoV-2 virus with varying clinical outcomes.^{1,2}

Protecting the animals in your care against SARS-CoV-2 (commonly referred to as COVID-19) is important. COVID-19 can have devastating ramifications to your animals. Vaccination can be an important step in your management approach to help mitigate COVID-19 from affecting your animals, alongside pandemic-enhanced biosecurity measures and your existing animal health protocols.

FOR EXPERIMENTAL USE ONLY. FOR VETERINARY USE ONLY. NOT FOR FURTHER DISTRIBUTION. WARNING! NOT FOR USE IN HUMANS.

Experimental vaccine from Zoetis available

Zoetis has developed an experimental COVID-19 vaccine for use in mink and is currently working with the USDA-CVB toward licensure. This same experimental vaccine has been used on an emergency basis in gorillas with approval by USDA-CVB. In the immediate term, since there is a need to protect animals now, the experimental vaccine may be made available under USDA authorization to zoos and conservatories on a case-by-case basis.

The experimental ready-to-use vaccine from Zoetis consists of a purified recombinant spike protein formulated with a proprietary adjuvant intended for use in animals. It is administered as a 1-mL dose subcutaneously with a booster 1-mL dose administered 21 days after initial vaccination.

> AVAILABLE IN 10-ML, 10-DOSE VIALS

8		Į	
	E		

Contact the Zoetis Center for Transboundary and Emerging Diseases at john.m.hardham@zoetis.com for more information or with questions.

